TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01465802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline or Doxycycline placebo BID for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alclometasone cream
Description: Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
Study: NCT02321579

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin B-6
Description: 50 mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin B-6
Description: 50 mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: 500 mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: 500 mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrins
Description: 50 mg/d
Study: NCT04400305

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Digital Health Online Platform
Description: The website has 10 lessons that the participant will gain access to on a bi-weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity
Study: NCT00323739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 10mg/kg, IV infusion, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 10 mg by mouth daily
Study: NCT03879681

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jelly confectionary Snakes
Description: The participants will be randomized by computer generated randomisation to receive either the jelly snake (n=120) or no intervention (n=120) apart from standard institutional management.~All children randomised into the snake group will be offered a chewy jelly snake once alert and cooperative in PACU or on the ward once University of Michigan Sedation Scale (UMSS) is 025,26. The UMSS is a simple observational tool that assesses the level of alertness on a five-point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation).~The children randomized into the control group will receive a chewy jelly snake as a treat at discharge.
Study: NCT03882359

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram
Description: Images will be recorded in parasternal long, short axis, apical four, two, and three chamber views according to the American Society of Echocardiography (ASE) 17 segment model. Each assessment will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2) in each of the pre-specified windows according to the 2014 ASE Sonographer Guidelines.~A baseline echocardiogram will be performed prior to the administration of DEFINITY® or MVT-100. Assessments will be made three times, once from 0 - 1 ½ minutes following injection, once between 1 ½ minutes to 3 minutes following IV injection and once from 3 - 4 ½ minutes following IV injection. Assessments at each time point will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2). Each round will include the views in the following order: parasternal long, parasternal short, apical 4, apical 2 and apical 3.
Study: NCT02845037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
Study: NCT03882359

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: Images will be recorded in parasternal long, short axis, apical four, two, and three chamber views according to the American Society of Echocardiography (ASE) 17 segment model. Each assessment will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2) in each of the pre-specified windows according to the 2014 ASE Sonographer Guidelines.~A baseline echocardiogram will be performed prior to the administration of DEFINITY® or MVT-100. Assessments will be made three times, once from 0 - 1 ½ minutes following injection, once between 1 ½ minutes to 3 minutes following IV injection and once from 3 - 4 ½ minutes following IV injection. Assessments at each time point will include one round of low MI imaging (\<0.3) and one round of very low MI imaging (\<0.2). Each round will include the views in the following order: parasternal long, parasternal short, apical 4, apical 2 and apical 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-100
Description: After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Definity
Description: After randomization, Definity, the active comparator, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
Study: NCT00838305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA and citalopram
Description: MDMA 1.5 mg/kg and citalopram 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
Study: NCT04314193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral prednisolone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
Study: NCT03037151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazaoprevir/Elbasavir
Description: treatment naive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazaoprevir/Elbasavir
Description: treatment naive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazaoprevir/Elbasavir/RBV
Description: treatment experienced

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazaoprevir/Elbasavir/RBV
Description: treatment experienced
Study: NCT01862978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT05702333

Intervention type: DRUG
Intervention: Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan
Description: Vasoactive-inotropic drugs were administered according to clinical decision of the doctor in charge.
Study: NCT02845037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
Study: NCT04317664

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: In-vehicle device
Description: The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data; and 3) A customized biweekly driving summary report.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: In-vehicle device
Description: The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data; and 3) A customized biweekly driving summary report.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Communication
Description: An individualized virtual training in communication strategies about driving safety along with a booster session will be delivered by a traffic safety communication specialist to subjects in the Feedback and Parent Communication Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
Study: NCT03431285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Group
Description: Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Group
Description: Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard IV hydration
Description: IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard IV hydration
Description: IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)
Study: NCT04499391

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Project ECHO
Description: Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation. This differentiates ECHO from traditional learning and facilitates rapid dissemination of medical knowledge and increased capacity to deliver best-practice care.studying innovative approaches.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project ECHO
Description: Project ECHO utilizes case-based, collaborative learning to support discussion of learners' challenges and barriers to guideline implementation. This differentiates ECHO from traditional learning and facilitates rapid dissemination of medical knowledge and increased capacity to deliver best-practice care.studying innovative approaches.
Study: NCT00460421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: High dose etoposide, Cyclophosphamide
Study: NCT04205292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hysteroscopic
Description: Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic
Description: Women in the intervention group will receive an inpatient treatment with two-dose of Methotrexate followed by hysteroscopic resection under ultrasound guidance
Study: NCT03724591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a high ligation of IMA
Description: total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: a low ligation of IMA
Description: total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
Study: NCT00432367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine
Description: Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine
Description: Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine
Description: Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use.
Study: NCT01211873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem (gadoterate meglumine)
Description: 0.1 mmol/kg by body weight, single IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem (gadoterate meglumine)
Description: 0.1 mmol/kg by body weight, single IV injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnevist (gadopentetate dimeglumine)
Description: 0.1 mmol/kg by body weight, single IV injection
Study: NCT03451474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper extremity nerve transfer surgery
Description: Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
Study: NCT04059861

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
Study: NCT04669756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovariopexy
Description: if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovariopexy
Description: if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovariopexy
Description: if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo operation
Description: in arm D sutures are transabdominal only
Study: NCT00288106

Intervention type: OTHER
Intervention: Follow-up
Description: No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
Study: NCT02046239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture Group

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Staple Group (control)
Study: NCT02525627

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trident cup, X3 inserts, 28 mm head
Description: Orthopaedic implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trident cup, X3 inserts, 40 mm head
Description: Orthopaedic implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symax stem
Description: Orthopaedic implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symax stem
Description: Orthopaedic implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accolade TMZF stem
Description: Orthopaedic implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accolade TMZF stem
Description: Orthopaedic implant
Study: NCT02944097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vineatrol 30 native powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vineatrol 30 micelles
Study: NCT01881178

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NOPALEA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NOPALEA
Study: NCT03962881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg recombinant hepatitis B vaccine at months 0, 1, and 6
Description: three-dose, 20 µg per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6
Description: four-dose, 20 µg per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6
Description: four-dose, 60 µg per dose
Study: NCT03090399

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FloTrac
Description: For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
Study: NCT01140815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Smith and Nephew Total Knee Replacement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deuce
Description: Smith and Nephew Bicompartmental Knee Replacement
Study: NCT04698005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25g Ketone monoester without added salts
Description: oral supplementation of ketone monoester

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
Study: NCT03350880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexibility training
Description: Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training
Description: Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
Study: NCT03367949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical guide designed from Impression inversion with markers
Description: Rather than using optical scan of the cast , We will use impression inversion technique with VPS impression and adding CBCT Markers on the tray
Study: NCT01590537

Intervention type: DRUG
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel

Intervention type: DEVICE
Intervention: Copper IUD
Description: Copper device, inserted intrauterine